SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9466)12/17/2002 6:07:18 PM
From: Biomaven  Respond to of 9719
 
From Bloomberg:

12/17 17:25
Corixa Has Shown Some Benefit From Cancer Drug, FDA Panel Says
By Kerry Dooley, kdooley@bloomberg.net or cell 202-297-1120
Bethesda, Maryland, Dec. 17 (Bloomberg) -- Corixa Corp. has shown that its experimental Bexxar drug may help some people who were not cured by earlier treatment for a cancer of the immune system, a U.S. government panel said.

A Food and Drug Administration advisory committee voted 10 to three on an agency question, seeking its view on how well Bexxar works. The FDA will use the panel's decision as it reviews Corixa's application for Bexxar approval.

bloomberg.com



       



To: Vector1 who wrote (9466)12/17/2002 6:09:13 PM
From: Vector1  Read Replies (2) | Respond to of 9719
 
TO ALL

BEXXAR gets affirmative vote from Advisory Committee.

On first question of "substantial evidence of clinical benefit the vote was 10-3 in favor.
On the second question "did the benefit of the drug outweigh the risk the vote was 13-0.

Congrats to all and most of all to those stricken with this terrible disease who will soon have another treatment option.

V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News